{"organizations": ["Keryx"], "uuid": "5b021b309f4ee289b53931e5b216ec48fd270a48", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530760?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Keryx privately sells $125mm of its convertible senior notes", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Keryx privately sells $125mm of its convertible senior notes", "spam_score": 0.0, "site_type": "news", "published": "2015-10-20T02:41:00.000+03:00", "replies_count": 0, "uuid": "5b021b309f4ee289b53931e5b216ec48fd270a48"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530760?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Keryx privately sells $125mm of its convertible senior notes", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": ["Keryx"], "text": "Keryx privately sells $125mm of its convertible senior notes Deal Date: Oct-01-2015 / Deal # 201530760 Executive Summary \nKeryx Biopharmaceuticals Inc. (renal disease therapies) sold $125mm of its convertible zero-coupon senior notes due 2020 to funds managed by the Baupost Group; the notes convert to common at $3.74. (The company's stock averaged $3.66 at the time of the sale.) Some of the proceeds will support US marketing of Auryxia (ferric citrate)--a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis--which was launched in December 2014.", "external_links": [], "published": "2015-10-20T02:41:00.000+03:00", "crawled": "2015-10-20T19:21:12.230+03:00", "highlightTitle": ""}